<DOC>
	<DOCNO>NCT01627665</DOCNO>
	<brief_summary>The study address impact genetical variation protein involve intestinal absorption two new anticoagulant : Dabigatran etexilate Rivaroxaban .</brief_summary>
	<brief_title>Pharmacogenomic Study PKD/PKC Dabigatran Etexilate Rivaroxaban</brief_title>
	<detailed_description>The study address impact genetical variation protein involve intestinal absorption two new anticoagulant : Dabigatran etexilate Rivaroxaban .</detailed_description>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Healthy participant Aged 1835 year inclusive Male Caucasian Body mass index ( BMI ) 18 27 kg per mÂ² inclusive .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>dabigatran</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>PKC</keyword>
	<keyword>PKD</keyword>
	<keyword>p-glycoprotein</keyword>
	<keyword>polymorphism</keyword>
</DOC>